1,879
Views
1
CrossRef citations to date
0
Altmetric
Review

Performance-based risk-sharing agreements in renal care: current experience and future prospects

ORCID Icon, , , , & ORCID Icon
Pages 197-210 | Received 05 Feb 2020, Accepted 12 Jan 2021, Published online: 05 Mar 2021

References

  • Gupta N, Wish JB. Do current quality measures truly reflect the quality of dialysis? Semin Dial. 2018;31(4):406–414.
  • Weiner D, Watnick S. The ESRD quality incentive program—can we bridge the Chasm? J Am Soc Nephrol. 2017(28): 1697–1706.
  • Desai AA, Garber AM, Chertow GM. Rise of pay for performance: implications for care of people with Chronic Kidney Disease. Clin J Am Soc Nephrol. 2007;2(5):1087–1095.
  • CMS.Org - Laws & Regulations [Internet]. [ cited 2020 Dec 30]. Available from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/05_LawsandRegs
  • Pham HH, Cohen M, Conway PH. The Pioneer Accountable Care Organization Model: improving Quality and Lowering Costs. JAMA. 2014;312(16):1635.
  • Executive Order on Advancing American Kidney Health [Internet]. 2019. Available from: https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/ (Accessed 05 February 2020).
  • Dabbous M, Chachoua L, Caban A, et al. Managed Entry Agreements: policy Analysis From the European Perspective. Value Health. 2020;23(4):425–433. .
  • Garrison LP, Towse A, Briggs A, et al., Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value Health. 16(5): 703–719. 2013. .
  • NHS England Cancer Drugs Fund Team. Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry [Internet]. NHS England; 2016. Available from: https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf(Accessed 05 February 2020).
  • Reckers-Droog V, Federici C, Brouwer W, et al. Challenges with coverage with evidence development schemes for medical devices: A systematic review. Health Policy Technol. 2020;9(2):146–156. S2211883720300137. .
  • Stafinski T, McCabe CJ, Menon D. Funding the Unfundable: mechanisms for Managing Uncertainty in Decisions on the Introduction of New and Innovative Technologies into Healthcare Systems. PharmacoEconomics. 2010;28(2):113–142.
  • Drummond M. When do performance-based risk-sharing arrangements make sense? Eur J Health Econ. 2015;16(6):569–571.
  • Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. Ann Inter Med. 2018;169(7):467. .
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535–b2535. .
  • Mannion R, Davies HTO. Payment for performance in health care. BMJ. 2008;336(7639):306–308.
  • Hahn jim. Pay-for-Performance in Health Care. Washington DC. Congressional Research Service (CRS); 2006.
  • Mendelssohn DC, Manns BJ. A Proposal for Improving Evidence Generation in Nephrology. Am J Kidney Dis. 2011;58(1):13–18. .
  • Mendelssohn DC, McFarlane P. Conditionally Funded Field Evaluations-A Solution to the Economic Barriers Limiting Evidence Generation in Dialysis?: FIELD EVALUATIONS IN DIALYSIS. Semin Dial. 2011;24(5):556–559. .
  • Boccato C, Evans DW, Lucena R, et al. Water and dialysis fluids. a quality management guide; 2015.
  • AdoptHTA. The AdHopHTA handbook: a handbook of hospital-based health technology assessment [Internet]. 2015. Available from: www.adhophta.eu.(Accessed 05 February 2020).
  • British Columbia Provincial Renal Agency (BCPRA) Hemodialysis Committee. In: Dialysate Water System Microbiology & Endotoxin Sampling. Vancouver: British Columbia Provincial Renal Agency (BCPRA); 2016.Pages 1-8
  • Nguyen NTQ, Cockwell P, Maxwell AP, et al. Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. In: Bolignano D, editor. PLOS ONE. Vol. 13. 2018. doi.org/10.1371/journal.pone.0207960.
  • ReNe (Renal Lombardy Network), Additional contributors from ReNe Network, Roggeri A, Roggeri DP, Zocchetti C, et al. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. J Nephrol. 2017;30(2):263–269.
  • Kalantar-Zadeh K, Kovesdy CP, Streja E, et al. Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease. Nephrol Dial Transplant. 2017;32(suppl_2):ii91–ii98. .
  • Fishbane S, Agoritsas S, Bellucci A, et al. Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial. Am J Kidney Dis. 2017;70(4):498–505. .
  • Hopkins RB, Garg AX, Levin A, et al. Cost-Effectiveness Analysis of a Randomized Trial Comparing Care Models for Chronic Kidney Disease. Clin J Am Soc Nephrol. 2011;6(6):1248–1257. .
  • Chen PM, Lai TS, Chen PY, et al. Multidisciplinary Care Program for Advanced Chronic Kidney Disease: reduces Renal Replacement and Medical Costs. Am J Med. 2015;128(1):68–76. .